Today: 27 June 2026
Walmart stock slips in thin New Year’s Eve session after CEO sale filing
31 December 2025
2 mins read

Walmart stock slips in thin New Year’s Eve session after CEO sale filing

NEW YORK, December 31, 2025, 14:18 ET — Regular session

  • Walmart (WMT) shares were down about 0.2% in afternoon trading, with year-end volumes muted.
  • An SEC filing showed CEO Doug McMillon sold shares last week under a pre-arranged trading plan.
  • Focus shifts to Walmart’s Feb. 19 earnings update and early-2026 macro signals.

Walmart Inc. (WMT) shares slipped 0.2% to $111.67 in afternoon trading on Wednesday, a subdued New Year’s Eve session for U.S. equities. The stock traded between $111.32 and $112.24 on volume of about 4.2 million shares.

The move mattered less for its size than for its timing. With the year closing and many desks lightly staffed, small headlines and routine flows can move prices faster than usual.

Walmart is widely watched as a read-through on U.S. household budgets and price sensitivity, given its scale in groceries and general merchandise. U.S. equity markets will be closed on Thursday for New Year’s Day and reopen on Friday, shortening the window for investors to adjust positions.

A filing with the U.S. Securities and Exchange Commission showed Chief Executive Doug McMillon sold 19,416 Walmart shares on Dec. 26 at a weighted average price of $111.8262. The transaction was made under a Rule 10b5-1 plan — a pre-set trading program that schedules trades in advance — and left McMillon with about 4.3 million shares held directly, the filing showed.

The disclosure arrived as Wall Street’s major indexes edged lower, with heavyweight technology stocks weighing on sentiment. “I do not expect that the last few days will have so much bearing on the performance of the next year,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters

Walmart’s decline tracked the broader consumer-staples group, with the Consumer Staples Select Sector SPDR Fund down about 0.2%. Costco and Amazon were modestly lower, while Target shares rose about 0.8% in the same window.

With little fresh company news on Wednesday, investors treated the Form 4 as a routine datapoint rather than a new thesis driver. That is typical for scheduled sales executed under 10b5-1 plans, though such filings can draw extra attention when markets are thin.

The next clear company catalyst is Walmart’s fiscal fourth-quarter earnings update on Feb. 19, when it is scheduled to release results and host a morning conference call, according to its events calendar.

Investors will be looking for updates on comparable sales — sales at stores and online channels open at least a year — and on how pricing and inventory are tracking after the holiday period. Margins and any commentary on demand trends typically carry more weight than near-term share swings in lightly traded sessions.

Macro drivers are also back in focus as the calendar turns. The Federal Reserve’s next scheduled policy meeting runs Jan. 27-28, and expectations for the rate path in 2026 remain a key input for equity valuations and consumer-facing names.

For Walmart, the setup into early January is straightforward: defensive-sector trading and index moves are likely to matter more day-to-day than incremental company headlines. Any shift in risk appetite when markets reopen on Friday could set the tone for retail shares heading into 2026.

The stock has stayed in a narrow band near $112 this week, reflecting year-end positioning rather than a decisive change in outlook. Traders will be watching for volume to normalize after the holiday and for attention to shift toward February’s earnings catalyst.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

Uber (NYSE:UBER) grabs $4.9 billion run as safety, robotaxis in focus

Uber (NYSE:UBER) grabs $4.9 billion run as safety, robotaxis in focus

27 June 2026
Uber surged 5.47% to $76.20 on Friday with trading volume 3.46 times its 65-day average, as investors weighed tighter U.S. driver background checks set to remove tens of thousands of gig workers starting Monday—raising potential impacts on trips, wait times, and margins while the stock remains 25.3% below its 52-week high.
Honeywell (NASDAQ:HON) heads into split week with $464 level on traders’ radar

Honeywell (NASDAQ:HON) heads into split week with $464 level on traders’ radar

27 June 2026
Honeywell’s two-for-one split launches Monday, giving investors one Honeywell Technologies share and one Honeywell Aerospace (HONA) share for every two old shares, with the combined package valued at $464.42 at Friday’s close; both stocks debut as separate S&P 500 members, while HONA joins the S&P 100, setting up a pivotal test for holders as the market reopens.
Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

27 June 2026
Snowflake Inc (NYSE:SNOW) surged 9.65% to $248.96 on Friday with trading volume five times the weekly average, driven by FTSE Russell’s U.S. index reconstitution, turning a negative week into a 7.2% gain since June 18, as investors await whether the stock can hold above its previous $225.95–$230.41 range when index-driven liquidity fades next week.
HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET
Previous Story

HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026
Next Story

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

Go toTop